Engflag

Orocan

Quick links to important sections

Orocan

Orocan_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orocan

Property Description
Active ingredient Fluconazole
Form Tablet, Capsule, Oral Suspension, IV Infusion
Pharmacological class Triazole Antifungal
General Purpose To control systemic fungal infections
Origin Synthetic

Defining Orocan: Identity, Active Ingredient, and Origin

Orocan is a single-component, prescription-only medication featuring the synthetic active ingredient Fluconazole, which is chemically classified as an anti-infective. This medication is a systemic antifungal agent. The product’s basic composition centers on the substance Fluconazole (INN), contained within an inert pharmaceutical base/vehicle appropriate for the dosage form.

Pharmacological Classification and Available Forms

Orocan belongs to the first-generation triazole antifungal class, a grouping within the broader azole antifungal family. Fluconazole is an agent for combating systemic fungal diseases. The drug is offered in several dosage forms, facilitating different routes of administration, including solid forms, such as tablets and capsules for oral use, and liquid preparations for intravenous infusion.

General Purpose of Orocan

The general purpose of this medication is to effectively control and suppress susceptible fungal infections. Fluconazole's fundamental action is related to its classification as a Fungal Ergosterol Synthesis Inhibitor. This means the drug halts the infectious process by targeting the fungus's ability to maintain its structure. By preventing the construction of the fungal cell membrane, the medication inhibits the organism's growth and proliferation, assisting the body in clearing the illness.

What side effects are possible with Orocan?

Official Adverse Reactions and Safety Profile

The possible side effects and safety profile of this medicine are formally documented by health authorities like the FDA and EMA, classifying adverse reactions primarily by frequency and the body system affected.

Frequency-Classified Effects

Side effects are categorized by how often they appear in clinical data. Common reactions, documented in official prescribing information, include headache and gastrointestinal disturbances such as nausea, abdominal pain, diarrhea, and vomiting. Uncommon effects may involve dizziness, somnolence (drowsiness), and certain blood chemistry changes. Rare adverse reactions are also officially listed and represent the most serious risks.

Serious Adverse Reactions

Official regulatory documents emphasize the potential for rare but serious adverse reactions that require vigilance. These include:

  • Hepatotoxicity: The risk of serious liver injury, ranging from elevated liver enzymes to rare cases of hepatic failure.
  • Severe Skin Reactions: Serious cutaneous events such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Cardiac Events: Potential for changes in heart rhythm, specifically QT prolongation and Torsade de Pointes.
  • Hematological Toxicity: Rare reports of blood disorders, including agranulocytosis and thrombocytopenia.

Safety Considerations and Constraints

The safety profile includes specific constraints. The medication is officially contraindicated in patients with a known hypersensitivity to the drug or related azole compounds. There is also a specific contraindication regarding concomitant use with certain medications that prolong the QT interval and are metabolized via CYP3A4 due to the increased risk of cardiac events.

Regarding patient groups, caution is noted in individuals with pre-existing hepatic or renal impairment. Furthermore, the label specifies that chronic, high-dose use of fluconazole during the first trimester of pregnancy is associated with a specific, rare risk of birth defects.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Orocan (Fluconazole) defines the overdose profile based on specific clinical manifestations and mandated emergency actions.

Documented Overdose Manifestations

Overdose events are formally associated with severe neurological and psychiatric disturbances. The documented presentations include the occurrence of hallucinations and episodes of paranoid behavior. The detection of these severe manifestations necessitates immediate action.

Emergency Response and Management

The drug’s official labeling states that immediate medical attention is required upon suspected or confirmed overdose. This mandate is driven by the severity of the documented central nervous system effects.

Management protocols are strictly limited to symptomatic and supportive treatment, as regulatory sources confirm that no specific antidote is known for Fluconazole overdose. Procedural interventions may include considering gastric lavage, if deemed clinically appropriate. Furthermore, hemodialysis is documented as an effective means to reduce plasma concentrations, potentially decreasing levels by approximately 50% over a 3-hour session, emphasizing the need for hospital monitoring.

Conclusion

The overall official overdose structure requires urgent medical evaluation for the documented psychiatric symptoms and is managed entirely through supportive care and specific plasma reduction procedures.

Therapeutic Uses of Orocan

What Orocan Treats: Main Uses and Benefits

Orocan is generally used to manage conditions associated with various types of fungal infections. It is applied across therapeutic areas involving heightened responses and offers symptomatic relief across key domains.

Therapeutic Focus and Relief

The medication is commonly used to help with serious, widespread fungal conditions like candidemia or Cryptococcal meningitis, providing systemic support during difficult episodes related to critical infections. It is also commonly used across conditions presenting with localized discomfort, such as oral thrush, esophageal candidiasis, and acute or recurrent vaginal yeast infections. The systemic support provided may assist with managing the overall symptom burden by easing symptoms like pain, burning, and difficulty swallowing, and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relevance for Symptomatic Discomfort Orocan supports the patient by addressing symptom clusters that may become intense or disruptive, particularly in recurrent mucosal infections or deep-seated fungal episodes.

The medication plays a role in managing the risk of fungal disease in immunocompromised patients (e.g., transplant or chemotherapy recipients) by acting as a preventive measure (prophylaxis). This strategy assists with maintaining functional stability in clinical contexts involving recurrent or episodic manifestations.

“The medication may be considered a systemic option for managing fungal pathogens, which assists with maintaining functional stability during symptomatic phases.”

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Orocan

The eligibility status for Orocan (Fluconazole) is strictly defined by regulatory documents based on a patient's medical history and current physiological status.

Absolute Contraindications

Orocan must not be used if there is a known hypersensitivity to fluconazole, related azole substances, or any excipients in the formulation. Use is also strictly contraindicated if the patient is simultaneously receiving specific medicines, such as cisapride or astemizole, that are metabolized by CYP3A4 and are known to prolong the heart's QT interval.

Population Restrictions

Population Group Regulatory Status
Renal or Hepatic Impairment Use with caution; requires close monitoring and specialized management due to altered drug clearance.
Cardiovascular Risk Use with caution in patients with pre-existing proarrhythmic conditions (e.g., QT prolongation or certain electrolyte abnormalities).
Pregnancy (High-Dose/Prolonged) Contraindicated except for life-threatening infections; use is not recommended for standard doses unless clearly necessary.
Lactation Permitted after a single, low dose (150 mg); not recommended for repeated or high-dose use.

Age-Based Eligibility

Use is established for adults and older adults. Pediatric use is established for many infections, although the label notes that safety and efficacy for the specific indication of genital candidiasis are not established in children. Neonates require specific, modified dosing schedules due to slower drug excretion.

What should I know about interactions with other medicines?

Orocan Interactions with other medicines and products

Orocan (Fluconazole) has documented pharmacokinetic interactions with a range of medicinal products, primarily due to its inhibitory effect on specific liver enzymes, namely CYP2C9, CYP2C19, and CYP3A4. This mechanism often results in increased plasma exposure (AUC and Cmax) of co-administered medicines that are metabolized by these enzymes.

Interaction-Related Restrictions

Several combinations are formally classified as contraindicated due to the risk of severe cardiotoxicity, including agents that prolong the QT interval such as Cisapride, Astemizole, Pimozide, Quinidine, and Erythromycin. Co-administration with Terfenadine is also prohibited when Fluconazole doses are 400 mg/day. Furthermore, co-administration with Lomitapide is contraindicated due to the potential for a substantial increase in Lomitapide exposure via CYP3A4 inhibition.

Key Pharmacokinetic Interactions

Fluconazole increases the exposure of various drug classes. For instance, co-administration with coumarin-type anticoagulants, like Warfarin, requires careful monitoring of prothrombin time (INR) due to increased exposure caused by CYP2C9 inhibition. Similarly, the plasma concentration of certain Statins and Phenytoin is officially documented to increase. Conversely, Rifampin is documented to decrease Fluconazole's plasma AUC by approximately 25% through enzyme induction. A diuretic such as Hydrochlorothiazide is documented to increase Fluconazole exposure by roughly 40% due to reduced renal clearance. The absorption of Fluconazole is not significantly affected by co-administration with food.

Mechanism of Action

Selective Inhibition of Fungal Lanosterol Demethylase

The core mechanism involves the active ingredient, Fluconazole, acting as a selective inhibitor of the fungal enzyme Lanosterol 14alpha-demethylase (or CYP51). By binding to the enzyme's heme iron center, the drug blocks the critical step in the ergosterol biosynthesis pathway. This action prevents the fungal cell from creating ergosterol, the essential sterol that maintains its structure and function, thereby compromising the pathogen's viability.

Disruption of Fungal Cell Membrane Integrity

The resulting lack of ergosterol, combined with the accumulation of toxic precursor sterols, functionally compromises the fungal cell membrane. This damage impairs the membrane's structural integrity, increases its permeability, and disrupts its regulatory function, leading to the functional suppression of the fungal cell. This impairment of the fungal structure and replication ability is the physiological consequence that mediates the suppression of the infectious organism's proliferation.

Dosage and Administration Information

The administration of Orocan is structured around established protocols defining routes, dosing, and patient-specific adjustments. The medicine is administered either via the oral route, using capsules, tablets, or a reconstituted suspension, or by intravenous infusion. Due to high oral bioavailability, the oral and intravenous forms are considered equivalent for use in most cases, and the oral forms may be taken with or without food as absorption is not clinically affected.

Dosing schedules frequently incorporate a loading dose on Day 1 to rapidly reach steady-state plasma concentrations, a procedural instruction for systemic treatment. This is followed by a maintenance dose, which typically ranges from 200 mg to 400 mg once daily for serious systemic or mucosal infections. In contrast, the use for acute vaginal candidiasis involves a single oral dose of 150 mg. The duration of administration is variable, ranging from a short, single course to prolonged or indefinite regimens for suppression of conditions like Cryptococcal meningitis.

Specific usage instructions involve dose adjustments for certain patient groups. For pediatric administration, the dose is calculated on a milligram-per-kilogram (mg/kg) body weight basis. Furthermore, patients receiving multiple-dose therapy who have renal impairment require a dose reduction determined by their creatinine clearance, a necessary step in the administration protocol.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Orocan (Fluconazole)

Evidence Supporting Use in Systemic Fungal Infections (Candidemia)

Research has been conducted through comparative Randomized Controlled Trials (RCTs) and large observational studies that sometimes include other systemic medications as control groups. These studies monitored adults with these serious infections. Research examined outcomes related to physical discomfort and functional imbalance by tracking key metrics, such as whether the fungus was cleared from the blood (mycological clearance). All-cause mortality (the survival status of the patient population at fixed time points) was monitored over defined time intervals. Findings indicate patterns observed in the studies regarding the clearance of the fungus, and studies monitored whether this varied based on the patient's underlying health status and the species of Candida involved.

Evidence Supporting Use in Mucosal and Localized Candidiasis

In localized mucosal infections, short-term, comparative RCTs were studied for whether they achieved clinical cure (resolution of visible lesions and outcomes related to physical discomfort). Research examined both immunocompromised and otherwise healthy adult and child populations. For Vulvovaginal Candidiasis, studies explored both single-dose and multi-dose regimens, tracking cure rates and recurrence over defined time intervals. Research highlights changes measured during the study period regarding the resolution of visible signs and the fungal culture status (mycological cure).

What Is Still Uncertain About Orocan Research

Official research and regulatory reviews have identified several limitations in the overall evidence landscape. Evidence is limited in fully characterizing long-term functional status and outcomes for specific pediatric and high-risk adult groups. The development of drug resistance was observed in some studies and remains an area of uncertainty. Research is ongoing to better understand the correlation between extended drug exposure and the potential for reduced susceptibility in fungal species, particularly C. glabrata and C. krusei. Finally, comparative evidence is lacking against the full spectrum of newer antifungal drugs for all indications.

Key Studies & References

  1. Diflucan (fluconazole) tablets, capsules, and powder for oral suspension - FDA Prescribing Information

Frequently Asked Questions (FAQ)

Common questions about Orocan (FAQ)

Q: What is Orocan used for?

Orocan is an oral antifungal medication primarily used to treat certain fungal infections in the body. It works by preventing the growth of the fungi that cause the infection.

Q: How should I take Orocan?

Orocan is typically taken once daily with a meal to enhance absorption. Always follow the specific instructions provided by your healthcare provider or as indicated on the prescription label. Do not crush, chew, or break the tablets unless directed to do so.

Q: What are the common side effects of Orocan?

Common side effects may include:

  • Headache
  • Nausea or upset stomach
  • Diarrhea
  • Rash

Contact your healthcare provider if these symptoms are persistent or worsen. In rare cases, more serious side effects may occur, such as signs of liver problems (e.g., severe fatigue, yellowing of skin/eyes, dark urine), which require immediate medical attention.

Q: Can I drink alcohol while taking Orocan?

It is generally recommended to avoid or limit alcohol consumption while taking Orocan. Combining alcohol and Orocan can increase the risk of liver side effects. Consult your healthcare provider about your alcohol use during treatment.

Q: What if I miss a dose of Orocan?

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time to make up for a missed one. If you frequently miss doses, speak with your healthcare provider.

Q: How long will I need to take Orocan?

The duration of treatment with Orocan depends on the type and severity of the fungal infection being treated. It can range from a few weeks to several months. Do not stop taking the medication early without consulting your healthcare provider, even if your symptoms improve, as the infection may return.

Q: Can Orocan be taken with other medications?

Orocan can interact with many other medications, which may change how they work or increase the risk of side effects. It is critical to inform your healthcare provider about all prescription, over-the-counter, and herbal supplements you are currently taking before starting Orocan. Specific attention is often paid to certain cholesterol-lowering drugs (statins), blood thinners, and proton pump inhibitors (PPIs).

How should Orocan be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal requirements for pharmaceutical products are strictly defined by regulatory agencies.

Requirement Official Statement Basis
Storage Temperature Must be kept at the temperature stated on the label, often defined as controlled room temperature.
Packaging Must remain in the original, protective, and non-reactive container to prevent contamination and degradation.
Child Safety Store securely out of the reach of children; controlled substances require locked, authorized access.
Disposal Method Do not dispose of in household trash or wastewater. Unused or expired medication must be transferred to an authorized collector or facility for destruction.
Handling Protect from excessive light, heat, and moisture. Stock must be rotated to ensure that the oldest products are used first, based on the labeled expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Orocan found in:

A-Z Index: